Gozde Kavgaci
Overview
Explore the profile of Gozde Kavgaci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sahin T, Guven D, Durukan M, Kavgaci G, Kaygusuz Y, Arik Z, et al.
Expert Rev Mol Diagn
. 2025 Feb;
:1-9.
PMID: 40007200
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for solid tumors, offering substantial survival benefits. Despite this progress, many patients do not achieve durable responses, highlighting the need...
2.
Kertmen N, Kavgaci G, Akin S, Coban G, Isikay A, Yazici G
Cancer Control
. 2025 Feb;
32:10732748251322072.
PMID: 39953938
Introduction: Recent advancements in immunotherapy have offered new possibilities for treating aggressive glioblastoma (GBM) and brain metastases. However, evaluating treatment responses remains complex, prompting the development of the immunotherapy-specific Response...
3.
Kertmen N, Kavgaci G, Koc I, Sagol S, Isikay A, Yazici G
Oncol Lett
. 2025 Jan;
29(3):146.
PMID: 39877061
Glioblastoma multiforme (GBM) is a tumor with a high refractory rate to immunotherapy and a low tumor mutational burden phenotype, leading to limited immunogenic neoantigens. The present study aimed to...
4.
Kavgaci G, Sahin T, Muderrisoglu T, Ileri S, Guven D, Aksoy S
Expert Rev Anticancer Ther
. 2024 Dec;
24(12):1319-1326.
PMID: 39673491
Background: The prognostic role of preoperative carcinoembryonic antigen (CEA) in breast cancer is recognized, but the impact of postoperative CEA levels on survival in early breast cancer is uncertain. Research...
5.
Kavgaci G, Sahin T, Sokmensuer C, Balaban H, Aksoy S
J Chemother
. 2024 Nov;
:1-6.
PMID: 39610055
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer represents the most prevalent subtype of breast cancer. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, in combination with endocrine therapy...
6.
Sahin T, Akyildiz A, Dogan O, Kavgaci G, Guven D, Aksoy S
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065675
Trastuzumab emtansine (T-DM1) is a mainstay therapy for HER2-positive metastatic breast cancer (mBC). However, identifying patients who will benefit most remains a challenge due to the lack of reliable biomarkers....
7.
Yildirim H, Buyukkor M, Kavgaci G, Celik B, Yucel K, Dursun B, et al.
Medicine (Baltimore)
. 2024 Jul;
103(30):e38828.
PMID: 39058877
The fact that the human epidermal growth factor receptor 2 (HER2)-low group, historically classified as HER2 negative in breast cancer histology, benefited from HER2-targeted treatments similarly to the HER2-positive group...
8.
Kavgaci G, Guven D, Kaygusuz Y, Karaca E, Dizdar O, Kilickap S, et al.
Support Care Cancer
. 2024 Jun;
32(7):467.
PMID: 38937345
Purpose: This study aimed to assess the effects of concurrent opioid analgesic (OA) use with immune checkpoint inhibitors (ICIs) on progression-free survival (PFS) and overall survival (OS). Methods: In this...
9.
Yildirim H, Kapar C, Koksal B, Seyyar M, Sanci P, Guliyev M, et al.
J Chemother
. 2024 Mar;
37(1):69-75.
PMID: 38497444
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the...
10.
Kavgaci G, Dizdar O, Yalcin S
Anticancer Drugs
. 2024 Mar;
35(5):459-461.
PMID: 38451823
Colorectal cancer (CRC) ranks third in global cancer prevalence, with 40% presenting as metastatic colorectal cancer (mCRC). KRAS mutations in mCRC patients confer resistance to anti-EGFR treatments. Promising inhibitors such...